ProQR Therapeutics N.V. (PRQR) Revenue History
Annual and quarterly revenue from 2013 to present
PRQR Revenue Over Time (2013–2025)
PRQR Revenue Growth History
6 of 11 years with positive growth- FY2013 revenue growth
- N/A
- FY2014 revenue growth
- N/A
- FY2015 revenue growth
- +2905.4%
- FY2016 revenue growth
- -75.7%
- FY2017 revenue growth
- -167.0%
- FY2018 revenue growth
- +423.2%
- FY2019 revenue growth
- -60.9%
- FY2020 revenue growth
- -46.8%
- FY2021 revenue growth
- +29.7%
- FY2022 revenue growth
- +169.2%
- FY2023 revenue growth
- +81.2%
- FY2024 revenue growth
- +190.2%
- FY2025 revenue growth
- -19.2%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $2.1M | -54.3% |
| Q4 2025 | $4.6M | +7.8% |
| Q3 2025 | $2.9M | -24.1% |
| Q2 2025 | $3.8M | -39.5% |
| Q1 2025 | $4.5M | +1.6% |
| Q4 2024 | $4.3M | +31.2% |
| Q3 2024 | $3.8M | +180.5% |
| Q2 2024 | $6.3M | +407.2% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2024)
PRQR's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
PRQR Revenue Analysis (2013–2025)
Current Revenue & Growth
As of June 12, 2026, ProQR Therapeutics N.V. (PRQR) generated trailing twelve-month (TTM) revenue of $13.4 million, reflecting significant decline in growth of -54.3% year-over-year. The most recent quarter (Q1 2026) recorded $2.1 million in revenue, down 55.5% sequentially.
Historical Growth Trajectory
PRQR's 5-year compound annual growth rate (CAGR) stands at +71.5%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +62.0% is below the 5-year average, signalling a growth deceleration in recent years. ProQR Therapeutics N.V.'s highest annual revenue of $18.9 million was recorded in 2024.
Revenue by Segment
PRQR's revenue is primarily driven by Up-front payments (75%), and Milestone payments (25%). With over half of revenue concentrated in Up-front payments, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including EDIT (+8.0% YoY), NTLA (+45.0% YoY), and CRSP (-88.9% YoY) — PRQR has underperformed the peer group in revenue growth. Compare PRQR vs EDIT →
PRQR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 PRQRCurrent | $13M | -54.3% | +71.5% | -275.9% | |
 EDIT | $41M | +8.0% | -14.9% | -245.2% | |
 NTLA | $68M | +45.0% | +3.1% | -651.7% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 ARWR | $829M | +14.1% | +56.6% | 11.9% |
PRQR Historical Revenue Data (2013–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $15.3M | -19.2% | $12.7M | 83.0% | $-42,154,897 | -275.9% |
| 2024 | $18.9M | +190.2% | $18.9M | 100.0% | $-30,472,000 | -161.2% |
| 2023 | $6.5M | +81.2% | $6.5M | 100.0% | $-31,859,000 | -489.1% |
| 2022 | $3.6M | +169.2% | $3.6M | 100.0% | $-65,159,000 | -1813.0% |
| 2021 | $1.3M | +29.7% | $1.3M | 100.0% | $-57,210,000 | -4285.4% |
| 2020 | $1.0M | -46.8% | $1.0M | 100.0% | $-42,368,000 | -4117.4% |
| 2019 | $1.9M | -60.9% | $-114,890,000 | -5943.6% | $-57,445,000 | -2971.8% |
| 2018 | $4.9M | +423.2% | $4.0M | 80.1% | $-36,293,000 | -734.5% |
| 2017 | $-1,529,000 | -167.0% | $-2,530,314 | 165.5% | $-40,498,000 | 2648.7% |
| 2016 | $2.3M | -75.7% | $1.0M | 43.8% | $-39,573,000 | -1734.1% |
| 2015 | $9.4M | +2905.4% | $8.9M | 94.9% | $-27,003,000 | -287.1% |
| 2014 | $313K | - | $313K | 100.0% | $-16,461,000 | -5259.1% |
| 2013 | $0 | - | $0 | - | $-3,239,000 | - |
What if you invested $1,000 in PRQR back in 2013?
Total return with dividends reinvested · 13+ years of data
Calculate ReturnsHow much would $100/month in PRQR be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs PRQR Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationPRQR vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowPRQR — Frequently Asked Questions
Quick answers to the most common questions about buying PRQR stock.
Is PRQR's revenue growth accelerating or slowing?
PRQR revenue is declining -54.3% year-over-year. TTM revenue fell to $13M, contrasting with the 5-year CAGR of +71.5%. The reversal reflects either macro headwinds or company-specific challenges.
What is PRQR's revenue history from 2013 to 2026?
ProQR Therapeutics N.V. (PRQR) revenue history spans 2013 to 2026. TTM revenue as of 2026 is $13M, growing at -54.3% YoY. The 5-year CAGR is +71.5%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is PRQR's long-term revenue growth rate (CAGR)?
ProQR Therapeutics N.V.'s 5-year revenue CAGR of +71.5% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -54.3% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for PRQR.
Why does PRQR's quarterly revenue fluctuate?
PRQR quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. ProQR Therapeutics N.V.'s revenue data from 2013 to 2026 shows full historical quarterly detail on this page.
How is PRQR's revenue distributed by segment?
PRQR reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does PRQR's revenue compare to industry peers?
ProQR Therapeutics N.V. (PRQR) with TTM revenue of $13M and -54.3% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.